ARTICLE | Company News
FDA approves Helsinn's Akynzeo combo for CINV
October 11, 2014 2:05 AM UTC
FDA approved Akynzeo netupitant/palonosetron from Helsinn Healthcare S.A. (Lugano, Switzerland) to treat chemotherapy-induced nausea and vomiting (CINV).
Akynzeo, previously known as NEPA, is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor antagonist. Helsinn and its partners already market palonosetron as Aloxi, Paloxi and Onicit in more than 65 countries to prevent CINV. ...